Selective Aromatase Inhibitors: Letrozole Anastrozole and Exemestane are selective aromatase inhibitors (AI) indicated as adjuvant therapy for postmenopausal women with early-stage, node-positive, and ER+ BC as well as in the advanced disease setting. Here, CYP19A1 is linked to breast cancer.